HC Wainwright Reiterates "Buy" Rating for Cibus (NASDAQ:CBUS)

HC Wainwright reissued their buy rating on shares of Cibus (NASDAQ:CBUS - Free Report) in a report published on Friday,Benzinga reports. The firm currently has a $25.00 target price on the stock. HC Wainwright also issued estimates for Cibus' Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.67) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.70) EPS and FY2029 earnings at $1.36 EPS.

Separately, Canaccord Genuity Group cut their price target on Cibus from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, January 22nd.

Cibus Stock Performance

NASDAQ CBUS traded up $0.07 during trading on Friday, reaching $2.12. The company's stock had a trading volume of 55,827 shares, compared to its average volume of 166,467. The business's fifty day moving average price is $2.33 and its 200-day moving average price is $3.31. Cibus has a twelve month low of $1.80 and a twelve month high of $23.18. The firm has a market cap of $56.09 million, a price-to-earnings ratio of -0.09 and a beta of 2.04.

Cibus (NASDAQ:CBUS - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.19). Cibus had a negative net margin of 10,724.78% and a negative return on equity of 28.17%. The company had revenue of $1.21 million during the quarter, compared to analyst estimates of $1.13 million. As a group, sell-side analysts forecast that Cibus will post -2.96 EPS for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Cibus

A number of hedge funds have recently added to or reduced their stakes in CBUS. HighTower Advisors LLC increased its position in Cibus by 20.6% during the 3rd quarter. HighTower Advisors LLC now owns 16,125 shares of the company's stock worth $52,000 after purchasing an additional 2,750 shares during the period. Charles Schwab Investment Management Inc. raised its position in Cibus by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company's stock worth $161,000 after acquiring an additional 6,276 shares in the last quarter. Barclays PLC raised its position in Cibus by 35.1% in the fourth quarter. Barclays PLC now owns 27,375 shares of the company's stock worth $76,000 after acquiring an additional 7,106 shares in the last quarter. Northern Trust Corp lifted its holdings in Cibus by 9.2% in the fourth quarter. Northern Trust Corp now owns 152,122 shares of the company's stock valued at $423,000 after acquiring an additional 12,832 shares during the period. Finally, IFP Advisors Inc purchased a new stake in shares of Cibus during the 4th quarter worth $36,000. Institutional investors and hedge funds own 33.81% of the company's stock.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.